TMCnet News
Prelude Therapeutics To Participate in Jefferies Healthcare ConferenceWILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 2023. Details are as follows: Dr. Vaddi, joined by Jane Huang, MD, President and Chief Medical Officer and Laurent Chardonnet, Chief Financial Officer, will host one-on-one meetings on June 7th. About Preude Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor; PRT3645, a brain penetrant CDK4/6 inhibitor; and PRT3789 a first-in-class SMARCA2/BRM protein degrader. For more information, visit our website and follow us on LinkedIn and Twitter. Investor Contact: Media Contact: 
|
